Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
A total of 11,018 paired SpO2-SaO2 measurements were analysed. All five pulse oximeters returned higher SpO2 values for patients with darker skin tones than patients with lighter skin tones, at any ...
NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve ...
“This is a historic moment for our company and for the patients we serve, as we fulfill our promise to translate our science into medicines that may make a meaningful difference in patients’ lives,” ...
The SOFA-2 score included new definitions, new variables, and revised thresholds to categorize the severity of organ dysfunction in critical illness. The updates reflected changes in practice, ...
Investing.com - H.C. Wainwright has reiterated its Buy rating and $120.00 price target on Cytokinetics (NASDAQ:CYTK), representing a significant upside from the current price of $53.89. According to ...
Investing.com - Jefferies has reiterated its Buy rating and $80.00 price target on Cytokinetics (NASDAQ:CYTK), which has shown impressive momentum with a 31% surge in the past week. According to ...
Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...
During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...
(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results